|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2
|
Van Loon K and Venook AP: Adjuvant
treatment of colon cancer: what is next? Curr Opin Oncol.
23:403–409. 2011.PubMed/NCBI
|
|
3
|
Garcia-Foncillas J and Diaz-Rubio E:
Progress in metastatic colorectal cancer: growing role of cetuximab
to optimize clinical outcome. Clin Transl Oncol. 12:533–542. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clevers H: The cancer stem cell: premises,
promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiao X, Katiyar S, Willmarth NE, et al:
c-Jun induces mammary epithelial cellular invasion and breast
cancer stem cell expansion. J Biol Chem. 285:8218–8226. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sullivan JP and Minna JD: Tumor
oncogenotypes and lung cancer stem cell identity. Cell Stem Cell.
7:2–4. 2010. View Article : Google Scholar
|
|
7
|
Li H and Tang DG: Prostate cancer stem
cells and their potential roles in metastasis. J Surg Oncol.
103:558–562. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zeki SS, Graham TA and Wright NA: Stem
cells and their implications for colorectal cancer. Nat Rev
Gastroenterol Hepatol. 8:90–100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Silva IA, Bai S, McLean K, et al: Aldehyde
dehydrogenase in combination with CD133 defines angiogenic ovarian
cancer stem cells that portend poor patient survival. Cancer Res.
71:3991–4001. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baba T, Convery PA, Matsumura N, et al:
Epigenetic regulation of CD133 and tumorigenicity of
CD133+ ovarian cancer cells. Oncogene. 28:209–218. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Landen CN Jr, Goodman B, Katre AA, et al:
Targeting aldehyde dehydrogenase cancer stem cells in ovarian
cancer. Mol Cancer Ther. 9:3186–3199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kurrey NK, Jalgaonkar SP, Joglekar AV, et
al: Snail and slug mediate radioresistance and chemoresistance by
antagonizing p53-mediated apoptosis and acquiring a stem-like
phenotype in ovarian cancer cells. Stem Cells. 27:2059–2068. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qiang L, Yang Y, Ma YJ, et al: Isolation
and characterization of cancer stem like cells in human
glioblastoma cell lines. Cancer Lett. 279:13–21. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim VN and Nam JW: Genomics of microRNA.
Trends Genet. 22:165–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shyu AB, Wilkinson MF and van Hoof A:
Messenger RNA regulation: to translate or to degrade. EMBO J.
27:471–481. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Garzon R, Fabbri M, Cimmino A, Calin GA
and Croce CM: MicroRNA expression and function in cancer. Trends
Mol Med. 12:580–587. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nicoloso MS, Spizzo R, Shimizu M, Rossi S
and Calin GA: MicroRNAs - the micro steering wheel of tumour
metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chan JA, Krichevsky AM and Kosik KS:
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu J, Getz G, Miska EA, et al: MicroRNA
expression profiles classify human cancers. Nature. 435:834–838.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang H, Li W, Nan F, et al: MicroRNA
expression profile of colon cancer stem-like cells in HT29
adenocarcinoma cell line. Biochem Biophys Res Commun. 404:273–278.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu F, Deng H, Yao H, Liu Q, Su F and Song
E: Mir-30 reduction maintains self-renewal and inhibits apoptosis
in breast tumor-initiating cells. Oncogene. 29:4194–4204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iliopoulos D, Lindahl-Allen M, Polytarchou
C, Hirsch HA, Tsichlis PN and Struhl K: Loss of miR-200 inhibition
of Suz12 leads to polycomb-mediated repression required for the
formation and maintenance of cancer stem cells. Mol Cell.
39:761–772. 2010. View Article : Google Scholar
|
|
24
|
Qian S, Ding JY, Xie R, et al: MicroRNA
expression profile of bronchioalveolar stem cells from mouse lung.
Biochem Biophys Res Commun. 377:668–673. 2008. View Article : Google Scholar
|
|
25
|
Silber J, Lim DA, Petritsch C, et al:
miR-124 and miR-137 inhibit proliferation of glioblastoma
multiforme cells and induce differentiation of brain tumor stem
cells. BMC Med. 6:142008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ji Q, Hao X, Zhang M, et al: MicroRNA
miR-34 inhibits human pancreatic cancer tumor-initiating cells.
PloS One. 4:e68162009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma L, Li N, He X and Zhang Q: miR-449b and
miR-34c on inducing down-regulation of cell cycle-related proteins
and cycle arrests in SKOV3-ipl cell, an ovarian cancer cell line.
Beijing Da Xue Xue Bao. 43:129–133. 2011.(In Chinese).
|
|
28
|
Bou Kheir T, Futoma-Kazmierczak E,
Jacobsen A, et al: miR-449 inhibits cell proliferation and is
down-regulated in gastric cancer. Mol Cancer. 10:292011.PubMed/NCBI
|
|
29
|
Chen H, Lin YW, Mao YQ, et al:
MicroRNA-449a acts as a tumor suppressor in human bladder cancer
through the regulation of pocket proteins. Cancer Lett. 320:40–47.
2012. View Article : Google Scholar
|
|
30
|
Matsushime H, Roussel MF, Ashmun RA and
Sherr CJ: Colony-stimulating factor 1 regulates novel cyclins
during the G1 phase of the cell cycle. Cell. 65:701–713. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Buchkovich K, Duffy LA and Harlow E: The
retinoblastoma protein is phosphorylated during specific phases of
the cell cycle. Cell. 58:1097–1105. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen PL, Scully P, Shew JY, Wang JY and
Lee WH: Phosphorylation of the retinoblastoma gene product is
modulated during the cell cycle and cellular differentiation. Cell.
58:1193–1198. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weinberg RA: The retinoblastoma protein
and cell cycle control. Cell. 81:323–330. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Harbour JW, Luo RX, Dei Santi A, Postigo
AA and Dean DC: Cdk phosphorylation triggers sequential
intramolecular interactions that progressively block Rb functions
as cells move through G1. Cell. 98:859–869. 1999. View Article : Google Scholar
|
|
35
|
Reis-Filho JS, Savage K, Lambros MB, et
al: Cyclin D1 protein overexpression and CCND1 amplification in
breast carcinomas: an immunohistochemical and chromogenic in situ
hybridisation analysis. Mod Pathol. 19:999–1009. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hosokawa Y and Arnold A: Mechanism of
cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells:
analysis of allele-specific expression. Genes Chromosomes Cancer.
22:66–71. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Betticher DC, Heighway J, Hasleton PS, et
al: Prognostic significance of CCND1 (cyclin D1) overexpression in
primary resected non-small-cell lung cancer. Br J Cancer.
73:294–300. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Leone G, DeGregori J, Yan Z, et al: E2F3
activity is regulated during the cell cycle and is required for the
induction of S phase. Genes Dev. 12:2120–2130. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Humbert PO, Verona R, Trimarchi JM, Rogers
C, Dandapani S and Lees JA: E2f3 is critical for normal cellular
proliferation. Genes Dev. 14:690–703. 2000.PubMed/NCBI
|
|
40
|
Oeggerli M, Tomovska S, Schraml P, et al:
E2F3 amplification and overexpression is associated with invasive
tumor growth and rapid tumor cell proliferation in urinary bladder
cancer. Oncogene. 23:5616–5623. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Olsson AY, Feber A, Edwards S, et al: Role
of E2F3 expression in modulating cellular proliferation rate in
human bladder and prostate cancer cells. Oncogene. 26:1028–1037.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cooper CS, Nicholson AG, Foster C, et al:
Nuclear overexpression of the E2F3 transcription factor in human
lung cancer. Lung Cancer. 54:155–162. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pierce AM, Gimenez-Conti IB,
Schneider-Broussard R, Martinez LA, Conti CJ and Johnson DG:
Increased E2F1 activity induces skin tumors in mice heterozygous
and nullizygous for p53. Proc Natl Acad Sci USA. 95:8858–8863.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fang Y, Xiang J, Chen Z, et al: miRNA
expression profile of colon cancer stem cells compared to non-stem
cells using the SW1116 cell line. Oncol Rep. 28:2115–2124.
2012.PubMed/NCBI
|
|
45
|
Ieta K, Tanaka F, Haraguchi N, et al:
Biological and genetic characteristics of tumor-initiating cells in
colon cancer. Ann Surg Oncol. 15:638–648. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
O’Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110.
2007.PubMed/NCBI
|
|
47
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
et al: Identification and expansion of human
colon-cancer-initiating cells. Nature. 445:111–115. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Vermeulen L, Todaro M, de Sousa Mello F,
et al: Single-cell cloning of colon cancer stem cells reveals a
multi-lineage differentiation capacity. Proc Natl Acad Sci USA.
105:13427–13432. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dalerba P, Dylla SJ, Park IK, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li C, Heidt DG, Dalerba P, et al:
Identification of pancreatic cancer stem cells. Cancer Res.
67:1030–1037. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang HJ, Ruan HJ, He XJ, et al:
MicroRNA-101 is down-regulated in gastric cancer and involved in
cell migration and invasion. Eur J Cancer. 46:2295–2303. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang X, Lam EK, Zhang J, Jin H and Sung
JJ: MicroRNA-122a functions as a novel tumor suppressor downstream
of adenomatous polyposis coli in gastrointestinal cancers. Biochem
Biophys Res Commun. 387:376–380. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Iorio MV, Ferracin M, Liu CG, et al:
MicroRNA gene expression deregulation in human breast cancer.
Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Michael MZ, SM OC, van Holst Pellekaan NG,
Young GP and James RJ: Reduced accumulation of specific microRNAs
in colorectal neoplasia. Mol Cancer Res. 1:882–891. 2003.PubMed/NCBI
|
|
56
|
Schepers AG, Snippert HJ, Stange DE, et
al: Lineage tracing reveals Lgr5+ stem cell activity in
mouse intestinal adenomas. Science. 337:730–735. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Driessens G, Beck B, Caauwe A, Simons BD
and Blanpain C: Defining the mode of tumour growth by clonal
analysis. Nature. 488:527–530. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Liu C, Kelnar K, Liu B, et al: The
microRNA miR-34a inhibits prostate cancer stem cells and metastasis
by directly repressing CD44. Nat Med. 17:211–215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Godlewski J, Nowicki MO, Bronisz A, et al:
Targeting of the Bmi-1 oncogene/stem cell renewal factor by
microRNA-128 inhibits glioma proliferation and self-renewal. Cancer
Res. 68:9125–9130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Sun F, Fu H, Liu Q, et al: Downregulation
of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett.
582:1564–1568. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Aslanian A, Iaquinta PJ, Verona R and Lees
JA: Repression of the Arf tumor suppressor by E2F3 is required for
normal cell cycle kinetics. Genes Dev. 18:1413–1422. 2004.
View Article : Google Scholar : PubMed/NCBI
|
